• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

成本效益阈值变化的决定因素。

Determinants of Change in the Cost-effectiveness Threshold.

作者信息

Paulden Mike, O'Mahony James, McCabe Christopher

机构信息

Department of Emergency Medicine, University of Alberta, Edmonton, AB, Canada (MP, CM).

Centre for Health Policy & Management, School of Medicine, Trinity College Dublin, Dublin, Ireland (JOM).

出版信息

Med Decis Making. 2017 Feb;37(2):264-276. doi: 10.1177/0272989X16662242. Epub 2016 Sep 27.

DOI:10.1177/0272989X16662242
PMID:27553208
Abstract

The cost-effectiveness threshold in health care systems with a constrained budget should be determined by the cost-effectiveness of displacing health care services to fund new interventions. Using comparative statics, we review some potential determinants of the threshold, including the budget for health care, the demand for existing health care interventions, the technical efficiency of existing interventions, and the development of new health technologies. We consider the anticipated direction of impact that would affect the threshold following a change in each of these determinants. Where the health care system is technically efficient, an increase in the health care budget unambiguously raises the threshold, whereas an increase in the demand for existing, non-marginal health interventions unambiguously lowers the threshold. Improvements in the technical efficiency of existing interventions may raise or lower the threshold, depending on the cause of the improvement in efficiency, whether the intervention is already funded, and, if so, whether it is marginal. New technologies may also raise or lower the threshold, depending on whether the new technology is a substitute for an existing technology and, again, whether the existing technology is marginal. Our analysis permits health economists and decision makers to assess if and in what direction the threshold may change over time. This matters, as threshold changes impact the cost-effectiveness of interventions that require decisions now but have costs and effects that fall in future periods.

摘要

在预算有限的医疗保健系统中,成本效益阈值应由将医疗保健服务挪用以资助新干预措施的成本效益来确定。运用比较静态分析方法,我们审视了该阈值的一些潜在决定因素,包括医疗保健预算、对现有医疗保健干预措施的需求、现有干预措施的技术效率以及新医疗技术的发展情况。我们考虑了这些决定因素中每一个发生变化后,预期会对阈值产生影响的方向。在医疗保健系统技术效率较高的情况下,医疗保健预算的增加会明确提高阈值,而对现有非边际医疗干预措施需求的增加则会明确降低阈值。现有干预措施技术效率的提高可能会提高或降低阈值,这取决于效率提高的原因、该干预措施是否已获资助,以及如果已获资助,它是否处于边际状态。新技术也可能提高或降低阈值,这取决于新技术是否是现有技术的替代品,以及同样地,现有技术是否处于边际状态。我们的分析使卫生经济学家和决策者能够评估阈值是否以及可能会朝什么方向随时间变化。这很重要,因为阈值变化会影响那些现在需要做出决策,但成本和效果却在未来时期才显现的干预措施的成本效益。

相似文献

1
Determinants of Change in the Cost-effectiveness Threshold.成本效益阈值变化的决定因素。
Med Decis Making. 2017 Feb;37(2):264-276. doi: 10.1177/0272989X16662242. Epub 2016 Sep 27.
2
Why Do Health Economists Promote Technology Adoption Rather Than the Search for Efficiency? A Proposal for a Change in Our Approach to Economic Evaluation in Health Care.为什么卫生经济学家提倡采用技术而非追求效率?关于改变我们在医疗保健经济评估方法的提议。
Med Decis Making. 2017 Feb;37(2):139-147. doi: 10.1177/0272989X16653397. Epub 2016 Jul 10.
3
Cost-effectiveness analysis and innovation.成本效益分析与创新
J Health Econ. 2008 Sep;27(5):1224-36. doi: 10.1016/j.jhealeco.2008.05.010. Epub 2008 Jun 5.
4
Economic evaluation: what does a nurse manager need to know?经济评估:护士长需要了解什么?
J Nurs Manag. 2005 Sep;13(5):419-27. doi: 10.1111/j.1365-2834.2005.00586.x.
5
Societal Preferences for Interventions with the Same Efficiency: Assessment and Application to Decision Making.社会对具有相同效率的干预措施的偏好:评估及其在决策中的应用
Appl Health Econ Health Policy. 2016 Jun;14(3):375-85. doi: 10.1007/s40258-016-0236-3.
6
Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology Assessment.将可负担性问题纳入卫生技术评估的成本效益分析中。
Value Health. 2019 Aug;22(8):898-905. doi: 10.1016/j.jval.2019.05.003. Epub 2019 Jul 30.
7
Health Economics as Rhetoric: The Limited Impact of Health Economics on Funding Decisions in Four European Countries.作为修辞学的卫生经济学:卫生经济学对四个欧洲国家资金决策的有限影响
Value Health. 2016 Dec;19(8):951-956. doi: 10.1016/j.jval.2016.08.001. Epub 2016 Sep 19.
8
Health care rationing: doing it better in public and private health care systems.医疗保健资源分配:在公共和私人医疗保健系统中做得更好。
J Health Polit Policy Law. 2013 Dec;38(6):1103-27. doi: 10.1215/03616878-2373157. Epub 2013 Aug 23.
9
Incremental cost-effectiveness ratios (ICERs): the silence of the lambda.增量成本效益比(ICERs):拉姆达的沉默。
Soc Sci Med. 2006 May;62(9):2091-100. doi: 10.1016/j.socscimed.2005.10.023. Epub 2005 Dec 1.
10
[Economic evaluation of medical therapy--methodological principles].[药物治疗的经济学评估——方法学原理]
Zentralbl Chir. 1995;120(8):577-83.

引用本文的文献

1
Cost-Effectiveness Analysis of Multiple Micronutrient Supplementation (MMS) Compared to Iron Folic Acid (IFA) in Pregnancy: A Systematic Review.孕期多种微量营养素补充剂(MMS)与铁叶酸(IFA)相比的成本效益分析:一项系统评价。
Int J Womens Health. 2025 Mar 6;17:639-649. doi: 10.2147/IJWH.S489159. eCollection 2025.
2
Reply to Comment on "A Framework for Fair Pricing of Medicines".对《药品公平定价框架》评论的回复
Pharmacoeconomics. 2024 May;42(5):607-609. doi: 10.1007/s40273-024-01369-9. Epub 2024 Mar 13.
3
A Framework for the Fair Pricing of Medicines.
药品合理定价框架
Pharmacoeconomics. 2024 Feb;42(2):145-164. doi: 10.1007/s40273-023-01325-z. Epub 2023 Dec 8.
4
Cost-effectiveness thresholds or decision-making threshold: a novel perspective.成本效益阈值或决策阈值:一种新视角。
Cost Eff Resour Alloc. 2023 Oct 3;21(1):72. doi: 10.1186/s12962-023-00472-6.
5
A Review of the Current Status of G6PD Deficiency Testing to Guide Radical Cure Treatment for Vivax Malaria.葡萄糖-6-磷酸脱氢酶缺乏症检测现状综述,以指导间日疟原虫疟疾的根治治疗
Pathogens. 2023 Apr 27;12(5):650. doi: 10.3390/pathogens12050650.
6
The ethics of aggregation in cost-effectiveness analysis or, "on books, bookshelves, and budget impact".成本效益分析中的汇总伦理,或“关于书籍、书架与预算影响”
Front Health Serv. 2022 Oct 13;2:889423. doi: 10.3389/frhs.2022.889423. eCollection 2022.
7
Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy.供给侧成本效益阈值:循证政策的问题。
Appl Health Econ Health Policy. 2022 Sep;20(5):651-667. doi: 10.1007/s40258-022-00730-3. Epub 2022 Jun 7.
8
Accounting for country- and time-specific values in the economic evaluation of health-related projects relevant to low- and middle-income countries.在对与中低收入国家相关的健康相关项目进行经济评估时,考虑国家和时间特异性价值。
Health Policy Plan. 2022 Jan 13;37(1):45-54. doi: 10.1093/heapol/czab104.
9
Affordability of Adult Tuberculosis Vaccination in India and China: A Dynamic Transmission Model-Based Analysis.印度和中国成人结核病疫苗接种的可负担性:基于动态传播模型的分析
Vaccines (Basel). 2021 Mar 11;9(3):245. doi: 10.3390/vaccines9030245.
10
Accounting for Timing when Assessing Health-Related Policies.评估与健康相关政策时考虑时间因素。
J Benefit Cost Anal. 2019 Jan 26;10(Suppl 1):73-105. doi: 10.1017/bca.2018.29.